This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Top U.S. and European nuclear medicine organizations have released joint guidelines on the use of fibroblast activation protein (FAP)-PET imaging in cancer patients. The guidelines -- issued by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) -- are hoped to clarify the role of FAP imaging in cancer diagnosis and may help lead to regulatory approval of new imaging agents, noted lead author Thomas Hope, MD, of the University of
Publication date: Available online 25 January 2025 Source: Clinical Radiology Author(s): Carl G. Glessgen, Joshy Cyriac, Shan Yang, Sebastian Manneck, Hildegard Wichtmann, Andreas M.
Fluorescence-guided imaging technology company Lumicell is highlighting the first U.S. launch of its real-time breast cancer visualization platform, LumiSystem. LumiSystem combines Lumisight, an optical imaging agent that fluoresces at sites of suspected cancerous tissue, and Lumicell Direct Visualization system, an imaging device that provides real-time fluorescence guidance for scanning the breast cavity during lumpectomy surgery, according to the firm.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content